Table 1.

In vivo effects of vitamin D analogues in animal models of cancer

Tumor, model	Analogue	Dose	Effect	Hypercalcemia	Ref.
Breast
N-methyl-N′-nitrosourea induced	EB1089	1 μg/kg p.o.	Tumor suppression	Marked	(71)
		Ro24-5531	1.25 and 2.5 nmol/kg diet	Reduced tumor incidence	None	(78)
		1α(OH)D₅	58.4 and 116.8 nmol/kg diet*	Reduced tumor incidence	None	(79)
MCF-7 xenografts	22-Oxa-1α,25(OH)₂D₃	1.0 μg/kg p.o.	Tumor suppression	None	(73)
		TX522	80 μg/kg/2 d i.p.	Tumor suppression	None	(77)
		TX527	25 μg/kg/2 d i.p.	Tumor suppression	Marked	(77)
MDA-MB-231 xenografts	EB1089	14 pmol/L/24 h, infusion	Inhibited skeletal metastasis	None	(72)
Prostate
LNCaP xenografts	EB1089	0.5 μg/kg i.p.	Tumor suppression	None	(81)
		EB1089	1 μg/kg p.o.	Tumor suppression	Mild	(86)
		LG190119	3 and 10 mg/kg p.o.	Tumor suppression	None	(86)
		LG190119	10 mg/kg p.o.	Reduced tumor incidence	None	(86)
PC-3 xenografts	Ro23-7553	1.6 μg/animal i.p.	Tumor suppression	None	(84)
MAT LyLu tumors in rats	EB1089	0.5 and 1.0 μg/kg i.p.	Inhibited lung metastasis	Marked	(82)
MDA-PCa 2b xenografts	JK-1626-2	4 μg/kg s.c.	Inhibited metastatic bone lesions	None	(83)
Colon
1,2-Dimethylhydrazine induced	22-Oxa-1α,25(OH)₂D₃	30 μg/kg i.p.^†	Reduced aberrant crypt foci	None	(91)
		Ro25-5317	3.5 nmol/kg diet	Reduced tumor incidence	None	(88)
		Ro25-9022	3.0 and 3.5 nmol/kg diet	Reduced tumor incidence	None	(88)
Azoxymethane induced	Ro24-5531	2.5 nmol/kg diet	Reduced tumor incidence	None	(89)
Azoxymethane induced		1α(OH)D₅	58.4 nmol/kg diet	Reduced aberrant crypt foci	None	(79)
LoVo xenografts	EB1089	0.1 and 0.5 μg/kg p.o.	Tumor suppression	None	(87)
HT-29 xenografts	Ro25-6760	0.1 and 0.2 μg/animal i.p	Tumor suppression	None	(90)
MC-26 xenografts	RO-4383561	0.02 μg E i.p.	Reduced tumor growth	None	(92)

↵* 1α(OH)D₅ 58.4 and 116.8 nmol/kg diet = 25 and 50 μg/kg diet.
↵† 22-Oxa-1α,25(OH)₂D₃ 30 μg/kg i.p. = 72.5 nmol/kg i.p.